Navigation Links
MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbul, Turkey.

The oral and poster presentation entitled, "Efficacy and safety of a novel submicron particle formulation of budesonide for nebulized delivery in a 6 week study in 1-18 year old asthmatic children" will be presented on Monday, June 25th at 4:30pm local time.

In addition, the Company has a second poster presentation available for viewing at the conference. The second poster entitled, "Safety, tolerability, and pharmacokinetics of a novel submicron particle formulation of nebulized budesonide for the treatment of asthma" will be presented on Saturday, June 23rd at 4:30pm local time.

Unit Dose Budesonide is the Company's proprietary nebulized version of budesonide intended to treat pediatric asthma in children from six months to eight years of age. UDB is designed to be administered more quickly and to provide efficacy at lower doses than conventional nebulized budesonide, which is the current leading treatment for pediatric asthma. Potential faster delivery and efficacy at a lower dose together may offer improved safety, compliance and convenience for young patients who suffer from asthma.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprie
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:12/3/2009)... , PISCATAWAY, N.J., Dec. 3 /PRNewswire-F...in Board: MLSS), the recognized leader in advanced...ad entered into a joint venture with China Nationa...nd Yichang Humanwell Pharmaceutical Co. Ltd., both...he "PRC"), to develop orthopedic and epidural drug...
(Date:12/3/2009)... , MAPLE GROVE, Minn., Dec. 3 /PRNewswire/...d the next phase of its strategic plan for central...ed release topiramate), an internally developed pr...ing developed with Upsher-Smith,s proprietary form...ical trial in early 2010 for the adjunctive treatm...
(Date:12/3/2009)... , ROCHESTER, N.Y., Dec. 3 /PRNewswire-FirstCal...ading provider of quantitative imaging for clinica...System and Method for 4D Reconstruction and Visual..., VirtualScopics, Vice President of Technology and...We are pleased that Japan has recognized the uniqu...
Breaking Medicine Technology:Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Upsher-Smith Announces Milestone in Development of CNS Strategy 2VirtualScopics Receives Issuance in Japan of Prominent Patent 2VirtualScopics Receives Issuance in Japan of Prominent Patent 3A study to prevent sudden death in sports by means of genetic testing 59151 1A study to prevent sudden death in sports by means of genetic testing 59151 2EPA awards competitive grants for students to design sustainable technologies that help environment and economy 10301 1Buffalo Bills Quarterback Trent Edwards Rallies Around The ALS Association 59149 1Buffalo Bills Quarterback Trent Edwards Rallies Around The ALS Association 59149 2Buffalo Bills Quarterback Trent Edwards Rallies Around The ALS Association 59149 3Buffalo Bills Quarterback Trent Edwards Rallies Around The ALS Association 59149 4
..., Dec. 1 S*BIO Pte Ltd today announced the initia...tent and orally-active JAK2 inhibitor, in leading ...onic idiopathic myelofibrosis (CIMF). , , Th...erability of SB1518 in patients with CIMF and is e...art of the study will assess the safety profile an...
...MEETING, Pa., Dec. 1 Genaera Corporation (Nasdaq... has begun in study MSI-1436C-102 (Study 102), the...uemine (MSI-1436) in overweight and obese type 2 d...treatment of type 2 diabetes and obesity which wor...and leptin pathways through the highly selective i...
Other Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:12/3/2009)...io Badescu Skin Care,s cult favorite Drying Lotion...receiving a 2009 ELLE Beauty Award , ...scu Skin Care,s Drying Lotion has long been a cult...ers, and skin care divas, but its selection by ELL...siderable leap into the mainstream limelight., , ,...
(Date:12/3/2009)...nomic downturn causes demand for affordable drug a...icut cites a sharp increase in demand for its serv...is which has led to an increase in alcoholic binge... (PRWEB) December 3, 2009 -- M...sees a huge spike in demand for its services due t...
(Date:12/3/2009)...linger about whether they cause brain cancer, , ...ether cell phones cause brain cancer has been a su...previous evidence suggesting that they don,t. ,...umors in Scandinavia found no substantial change i...spread, according to the report in the Dec. 3 onli...
(Date:12/3/2009)...f., Dec. 3 The Board of...udies unanimously voted to elect three new member...red Dotzler is co-founder and Managing Director o... investing $650 million from three funds in early ...Dotzler founded Medicus Venture Partners in 1989. ...
(Date:12/3/2009)...nalysis understates key factors contributing to in...wswire/ -- A new actuarial analysis by Oliver Wyma...n the new individual market will be 54 percent hig...ation of healthcare reform under the Patient Prote...he impact of medical inflation. This would transl...
Breaking Medicine News(10 mins):Health News:Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 2Health News:No Increase in Brain Tumors Seen From Cell Phones 2Health News:No Increase in Brain Tumors Seen From Cell Phones 3Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4
... high levels of D-dimer face greatest chance of tr...s) -- Levels of certain blood markers may increase...acement therapy to relieve symptoms of menopause, ...presented Saturday at the American Society of Hema...
...er 8, 2007 There is a clear link between GABA a c...at inhibits neurons in the brain and nicotine de...the American College of Neuropsychopharmacology (A...urable effects of nicotine and help people break t...
... proteins could determine if more invasive treatme...Y, Dec. 7 (HealthDay News) -- It may be possible t...g to a Duke University Medical Center-led study. ... -- may provide a simple follow-up for patients wh...
.... 7 Universal Health,Services, Inc. (NYSE: UHS )...rized an additional 5 million share repurchase pro...under previously announced authorizations.,Pursuan... transactions., Universal Health Services, Inc. i...
... held Wednesday, December 12 at Facility, PLANO, ...ealth and Rehab Center in Dallas will have a safer...ogram that ViewPoint Bank is,sponsoring at the fac...in the nation,s senior housing facilities., "Crim...
... A recent study by Best,Practices, LLC found that...roduct Introduction team was one of the most impor...Ensuring a Successful New Product Launch,Through E...e success of product launches., You can download ...
Other Medicine News:Health News:Blood Markers Might Predict Clotting Risk With HRT 2Health News:Blood Markers Might Predict Clotting Risk With HRT 3Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Blood Test to Detect Lung Cancer Being Eyed 2Health News:ViewPoint Bank Funds Senior Crimestoppers Program at Meadows Health and Rehab Center in Dallas 2Health News:Best Practice Database: Complimentary Excerpt of 'Ensuring a Successful New Product Launch Through Effective Processes and Authority Roles' 2
Josephine Vest V-65
Female Bra Vest
Scrotum Support
Support Brief
Medicine Products: